Pharmacy Benefit Management: An Overview

Pharmacy benefit management (PBM) plays an important role in the healthcare industry by helping manage prescription drug costs and improving patient outcomes. PBMs act as intermediaries between drug makers, pharmacies, and health insurance plans. In this article, we will explore what PBMs are, how they operate, and their impact on patients and the overall healthcare system.

What is a Pharmacy Benefit Manager?

A pharmacy benefit manager, or PBM, is a third-party administrator of prescription drug programs. PBMs help negotiate prices and rebates for prescription medications, develop formularies to determine which drugs are covered by a given plan, and process and pay prescription drug claims. They work with health insurers, employers, labor unions, and government programs like Medicare and Medicaid to manage drug benefits for plan sponsors and members.

The main services provided by PBMs include negotiating rebates and discounts from drug manufacturers, developing drug formularies that determine tiered cost-sharing structures, contracting with retail pharmacies, mail-order fulfillment, claims processing, and performing drug utilization reviews. By consolidating the prescription drug purchasing of numerous health plans, PBMs aim to reduce costs through their size and scale.

Negotiating Rebates and Discounts

One of the key roles of PBMs is negotiating rebates and discounts from drug manufacturers. These rebates are contingent on a drug being included on a health plan's formulary or gaining preferred status with reduced copays. The rebates are typically passed on in part to health plans and employers. However, the exact rebate amounts are usually kept confidential between PBMs and drug makers due to competitive pressures. Critics argue this lack of transparency allows PBMs and manufacturers to profit disproportionately.

Developing and Maintaining Formularies

PBMs develop formularies or preferred drug lists for their health plan clients. Formularies determine which medications are covered, their placement into tiers or cost-sharing levels like generic, preferred brand, non-preferred brand, and specialty drugs. Drugs that offer higher rebates tend to receive preferred placement, lower copays, and less hurdles like prior authorization on formularies. The goal is to incentivize utilization of lower-cost generics and brands while making high-cost drugs less attractive to consumers. However, the choice of drugs can impact patients' access and choice of medication prescribed by their doctor.

Contracting with Pharmacies

PBMs negotiate contractual rates with retail pharmacies, mail-order pharmacies, and specialty pharmacies. The contracts establish reimbursement rates for filling prescriptions covered under PBM plans. They typically favor lower rates with mail-order and specialty pharmacies they own over independent pharmacies. This allows PBMs to steer volume to their affiliated pharmacies, earning additional profits on dispensing fees. However, patients may face higher out-of-pocket costs or limited choice of pharmacy with PBM preferred networks.

Processing and Paying Claims

Once prescriptions are filled, PBMs process and pay claims using their contractual rates and formulary eligibility. They adjudicate claims in real-time to determine coverage, apply member cost-shares like copays and maximum out-of-pocket amounts. Denied claims may require an appeal or prior authorization to gain coverage. PBMs also conduct drug utilization reviews to monitor for fraud, waste, abuse, and ensure formulary compliance for safety and cost-effectiveness. This part of the process ensures appropriate payment while upholding plan rules.

Impacts of PBM Activities

PBM activities aim to control prescription drug spending increases that continue rising faster than overall health costs. Studies show PBM negotiated rebates have helped lower costs. However, their strategies can influence clinical prescribing as formularies do not always prioritize best treatments. Steering volume can benefit affiliated pharmacies over patient choice and independent businesses. While branded drug rebates save money upfront, critics argue they may delay generics and biosimilars that could offer even greater long-term savings. Overall, PBMs succeed in cost management but face challenges regarding objectivity, transparency, and their influence over healthcare markets.

Potential Solutions and Ongoing Debates

To address criticisms around transparency and potential conflicts of interest, policymakers have debated several approaches. Proposals include requiring PBMs to pay pharmacies their acquisition costs plus a reasonable dispensing fee so they are not dependent on rebates to offset reimbursements below costs. Others call for greater audit powers over PBM finances and contracts to verify passed-through rebate amounts. Demands for transparency into contract terms aim to surface the real costs versus list prices actually paid. Formulary independence remains a hot topic as cost control impacts clinical freedom.

On the other hand, PBMs argue greater transparency would undermine their ability to negotiate competitive rebates and discounts, leading to higher drug spending overall. They emphasize the need to balance cost controls with clinical flexibility. Ongoing attempts to independently review PBM contracts and audit finances seek a balanced approach. But disagreements over their role in the system will likely remain a subject of debate as healthcare costs continue rising for consumers, employers, and taxpayers who depend on PBM services as healthcare intermediaries.

In summary, pharmacy benefit managers play an important administration role between drug makers, pharmacies, and health plans. While they succeed in controlling costs through rebates and formulary management, their business practices also face scrutiny regarding transparency, conflicts of interest, and clinical independence. As healthcare spending rises, determining the appropriate level of oversight and reform to balance their cost-saving role while ensuring fair treatment of other stakeholders will likely remain an ongoing public policy discussion. PBMs remain central healthcare intermediaries but achieving greater objectivity in their operations presents ongoing challenges.